10-Q: Tenax Therapeutics Boosts Cash, Advances PH-HFpEF Trial

Tenax Therapeutics reported increased cash reserves and accelerated R&D spending to advance its Phase 3 levosimendan program for pulmonary hypertension, despite widening net losses.

Summary

• Cash and cash equivalents increased to $105.5 million as of June 30, 2025, up from $94.9 million at December 31, 2024.
• Net loss for the six months ended June 30, 2025, widened to $21.3 million, compared to $7.4 million for the same period in 2024.
• Research and development expenses increased by 136% to $11.8 million for the six months ended June 30, 2025, driven by the ongoing Phase 3 LEVEL trial and preliminary work for LEVEL-2.
• General and administrative expenses surged by 340% to $11.3 million for the six months ended June 30, 2025, primarily due to increased stock-based compensation and capital market expenses.
• The company completed a private placement financing in March 2025, raising $23.2 million net, intended to fund the levosimendan program.
• Enrollment for the Phase 3 LEVEL study continues, with completion of 230 patients expected in the first half of 2026.
• A second global Phase 3 study, LEVEL-2, is on track to commence in 2025.
• Management believes current capital is sufficient to fund operations through 2027.

Sentiment

Score: 6

Explanation: While the company has a strong cash position and is advancing its key clinical program, the significant increase in net loss and operating expenses, coupled with the deprioritization of imatinib, indicates high burn rate and ongoing financial challenges typical of a development-stage biotech. The extended cash runway is a positive, but future capital needs are explicitly stated.

Positives

• Strong cash position of $105.5 million as of June 30, 2025, providing liquidity through 2027.
• Successful capital raises, including $23.2 million net from the March 2025 private placement, bolstering financial resources.
• Advancement of the prioritized Phase 3 LEVEL clinical trial for levosimendan, with patient enrollment continuing and high rates of study continuation.
• Plans to initiate a second global Phase 3 study (LEVEL-2) for levosimendan in 2025, indicating progress in the development pipeline.
• Increased interest income by 749% to $1.9 million for the six months ended June 30, 2025, reflecting effective cash management.

Negatives

• Significant increase in net loss to $21.3 million for the six months ended June 30, 2025, up from $7.4 million in the prior year.
• Substantial increase in operating expenses, with R&D up 136% to $11.8 million and G&A up 340% to $11.3 million for the six months ended June 30, 2025.
• Increased cash burn from operating activities, with net cash used rising to $13.2 million for the six months ended June 30, 2025, from $8.2 million in the prior year.
• Accumulated deficit grew to $336.1 million as of June 30, 2025, indicating continued cumulative losses.
• Deprioritization of the Phase 3 clinical trial for imatinib, potentially narrowing the future product pipeline.
• Significant stock-based compensation expense, increasing by $8.5 million for the six months ended June 30, 2025, compared to the prior year.

Risks

• Future capital requirements are substantial and depend on the success and timing of clinical trials, regulatory approvals, and commercialization efforts.
• Uncertainty regarding the duration and completion costs of current or future clinical stages of product candidates.
• The probability of success for each product candidate and clinical trial is affected by factors such as early clinical data quality, investment, competition, manufacturing, and commercial viability.
• Potential for dilution for stockholders if additional funds are raised by issuing common stock or other convertible securities.
• Risk of incurring significant interest expense and restrictive covenants if additional capital is raised through debt financings.
• Necessity to relinquish rights or grant unfavorable licenses if additional funds are raised through collaboration and licensing arrangements.
• The License agreement for levosimendan can be terminated by either party if no US regulatory approval is granted by September 20, 2030.
• Cash balances exceeding FDIC insurance limits, with $15.9 million uninsured as of June 30, 2025.

Future Outlook

Management expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances product candidates through development and clinical trials. The company intends to submit marketing authorization applications following the completion of two Phase 3 trials for levosimendan and, when appropriate, a single Phase 3 trial for imatinib. Current capital is believed to be sufficient to fund operations through 2027, but substantial additional capital will be needed to finalize levosimendan development, commence commercialization, potentially develop imatinib, and pursue other product candidates.

Management Comments

• We intend to use the net proceeds from the March 2025 Offering to advance our Phase 3 oral levosimendan program, by completing our ongoing Phase 3 LEVEL study of TNX-103 in pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF) and initiating a second global Phase 3 study, LEVEL-2.
• Patient enrollment in our Phase 3 LEVEL study continues, with high rates of study and therapy continuation during the blinded and open-label extension stages.
• We expect to complete enrollment of 230 patients in the first half of 2026.
• We remain on track to commence LEVEL-2 this year.
• Given our resources on June 30, 2025, we believe we can continue our operations through 2027.
• Our ability to continue to pursue development of our products, including completion of the second global Phase 3 trial (LEVEL-2), beyond 2027, will depend on obtaining license income, income from warrants exercised by investors should they elect to do so, or outside financial resources.

Industry Context

Tenax Therapeutics operates in the highly capital-intensive and high-risk biotechnology and pharmaceutical industry, specifically targeting cardiopulmonary diseases like pulmonary hypertension. The strategy of developing already-approved drugs (levosimendan and imatinib) for new indications is a common de-risking approach in the industry, leveraging established safety profiles. The significant increase in R&D and G&A expenses, coupled with widening losses, is typical for clinical-stage biopharmaceutical companies as they advance costly Phase 3 trials. The reliance on equity financing for operations and clinical development is also standard for companies without commercialized products. The focus on PH-HFpEF, a condition with high unmet medical need, positions Tenax in a competitive but potentially lucrative market segment.

Comparison to Industry Standards

• The company's cash burn rate of $13.2 million in operating activities for six months is typical for a Phase 3 clinical-stage biotech, comparable to companies like United Therapeutics (though much larger, also focuses on PAH) or smaller biotechs like Acceleron Pharma (acquired by Merck, but previously focused on pulmonary diseases).
• The significant increase in R&D expenses (136%) and G&A expenses (340%) is consistent with the ramp-up of a global Phase 3 trial (LEVEL) and the initiation of another (LEVEL-2), which are inherently expensive milestones in drug development.
• The reliance on equity financing, as evidenced by the $23.2 million net raise in March 2025 and previous large raises, is a standard funding mechanism for pre-revenue biopharmaceutical companies, similar to how companies like Gossamer Bio or Eledon Pharmaceuticals fund their clinical pipelines.
• The accumulated deficit of $336.1 million is common for a company that has been in development since 1990 without a commercialized product, reflecting the long and costly drug development cycle.
• The projected cash runway through 2027 is a positive indicator, providing a longer operational window compared to many smaller biotechs that often report 12-18 months of runway.

Management Changes

Corporate Governance

Legal Proceedings

• No material pending legal proceedings to which the company is a party or to which any of its property is subject.

Related Party Transactions

• No specific related party transactions were disclosed in this filing beyond standard compensation and stock option grants to employees and directors.

Stakeholder Impact

• Shareholders: Experience dilution from recent and potential future equity raises. Benefit from increased cash runway and progress in clinical trials, but face risks from widening losses and the long development timeline.
• Employees: Benefit from increased stock-based compensation and new inducement grants, indicating continued investment in talent.
• Creditors: No significant debt mentioned, reducing immediate risk from this group.
• Customers (future): Potential benefit from new cardiopulmonary therapies if levosimendan achieves regulatory approval.
• Suppliers/CROs: Increased R&D spending indicates more business for clinical research organizations and suppliers involved in drug development.

Next Steps

• Complete enrollment of 230 patients in the Phase 3 LEVEL study in the first half of 2026.
• Initiate a second global Phase 3 study, LEVEL-2, in 2025.
• Submit marketing authorization applications following completion of two Phase 3 levosimendan trials and, when appropriate, a single Phase 3 imatinib trial.
• Continue to evaluate the contingency for liquidated damages provisions related to registration rights agreements.
• Seek additional license income, warrant exercise income, or outside financial resources to fund operations beyond 2027.

Key Dates

Recommendation

While Tenax Therapeutics has significantly bolstered its cash reserves through recent financings, providing a runway through 2027, the company continues to incur substantial and increasing net losses due to accelerated R&D and G&A expenses. The advancement of the Phase 3 LEVEL trial for levosimendan is a positive step, but the deprioritization of imatinib and the long, costly path to potential commercialization for levosimendan introduce considerable risk. The stock is a 'hold' for investors who are comfortable with high-risk, development-stage biotechnology companies and believe in the long-term potential of levosimendan, but new investors should await further clinical milestones and a clearer path to profitability before considering a 'buy' given the current burn rate and accumulated deficit.

Keywords

Tenax Therapeutics, TENX, 10-Q, Quarterly Report, Biotechnology, Pharmaceuticals, Cardiopulmonary Therapies, Pulmonary Hypertension, PH-HFpEF, Levosimendan, TNX-103, Phase 3 Clinical Trial, LEVEL Study, Drug Development, Clinical Stage, SEC Filing, Financial Results, Cash Position, R&D Expenses, Capital Raise, Orion Corporation, Imatinib